

## EXOSENS ANNOUNCES THE IMPLEMENTATION OF A LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX

PRESS RELEASE MÉRIGNAC, FRANCE – JULY 8<sup>th</sup>, 2024

**EXOSENS S.A.** (Euronext Paris: FR001400Q9V2) announces today the implementation of a liquidity agreement with Kepler Cheuvreux to enhance the liquidity of EXOSENS shares admitted to trading on Euronext Paris for an initial period ending on December 31<sup>st</sup>, 2024, renewable by tacit agreement for successive periods of one year.

The implementation of this liquidity agreement, pursuant to the authorization granted by the General Meeting held on May 31st, 2024, will be carried out in accordance with the legal framework in force, and more particularly to the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014 on market abuse (MAR), Commission Delegated Regulation (EU) 2016/908 of February 26, 2016 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council, Articles L. 22-10-62 et seq. of the French Commercial Code and French Financial Markets Authority (AMF) decision no. 2021-01 of June 22, 2021, applicable as of July 1, 2021 renewing the introduction of liquidity contracts for equity securities as an accepted market practice (the "AMF Decision").

The following resources will be allocated to the liquidity account:

- 2 000 000 euros

The execution of the liquidity contract could be suspended under the conditions set out in Article 5 of AMF Decision.

The liquidity contract could be terminated:

- at any time by EXOSENS upon two (2) business days' notice
- at any time by Kepler Cheuvreux, subject to thirty (30) calendar days' notice
- without notice and without formality if the Exosens shares are transferred to another stock market





## **ABOUT EXOSENS:**

Accompanied by Groupe HLD since 2021, Exosens is a high-tech company, with more than 85 years of experience in the innovation, development, manufacturing and sale of high-end electro-optical technologies in the field of amplification, detection and imaging. Today, it offers its customers detection components and solutions such as travelling wave tubes, advanced cameras, neutron & gamma detectors, instrument detectors and light intensifier tubes. This allows Exosens to respond to complex issues in extremely demanding environments by offering tailor-made solutions to its customers. Thanks to its sustained investments, Exosens is internationally recognized as a major innovator in optoelectronics, with production and R&D carried out on 10 sites, in Europe and North America and with over 1,600 employees.

Exosens is listed on compartment A of the regulated market of Euronext Paris (Ticker: EXENS – ISIN: FR001400Q9V2) and is a member of Euronext Tech Leaders segment.

For more information: exosens.com

## Disclaimer

This press release does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in securities in France, the United States or any other jurisdiction.

## Forward-looking statements

Certain information included in this press release are not historical facts but are forward-looking statements. These forward-looking statements are based on current beliefs, expectations and assumptions. Forward-looking statements speak only as of the date of this press release and Exosens expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements included in this press release to reflect any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. Such forward-looking statements are for illustrative purposes only. Forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Exosens. These risks and uncertainties include those discussed or identified under Chapter 3 "Risk factors" in Exosens' registration document, approved by the French Financial Markets Authority (AMF) on May 22th, 2024, which is available on the website of Exosens (www.exosens.com) and of the AMF (www.amf-france.org).

